Long-Term Results of Photodynamic Therapy for Subfoveal Choroidal Neovascularization With Pathologic Myopia

Giansanti, Fabrizio; Virgili, Gianni; Donati, Maria Carla; Giuntoli, Matteo; Pieretti, Giulia; Abbruzzese, Giacomo; Menchini, Ugo

doi:10.1097/iae.0b013e3182411cee

Cited by 31 publications

(22 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean LogMAR VA for myopic CNV lesions treated with PDT ranges from 0.25 to 0.72 in the literature (Table 2), [19][20][21][22][23][24][25][26][27][28][29][30] which is comparable to the overall results in this series (mean LogMAR VA 0.72 at 2 years). In studies that have analyzed visual outcomes based on the location of the CNV lesion, final VA for subfoveal myopic CNV ranged from 0.43 to 0.92, 20,22,24,29 whereas the final VA for extrafoveal myopic CNV was slightly better, ranging from 0.25 to 0.72.…”

Section: Discussionsupporting

confidence: 78%

“…In studies that have analyzed visual outcomes based on the location of the CNV lesion, final VA for subfoveal myopic CNV ranged from 0.43 to 0.92, 20,22,24,29 whereas the final VA for extrafoveal myopic CNV was slightly better, ranging from 0.25 to 0.72. 19,20,23 Similar to these earlier studies, our results showed a significant difference in visual outcomes based on the location of the CNV lesion, with extrafoveal CNV having better outcomes compared with subfoveal CNV (LogMAR VA 0.45 vs 1.05 at 24 months).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of foveal-sparing with foveal-involving photodynamic therapy for myopic choroidal neovascularization

Tan

Chew

2013

Eye

View full text Add to dashboard Cite

Purpose To evaluate the visual outcomes of choroidal neovascularization (CNV) secondary to pathological myopia in eyes treated with photodynamic therapy (PDT), and to determine the effect of lesion location and foveal involvement on visual prognosis. Methods Interventional case series of 24 consecutive patients with myopic CNV treated with PDT. The main outcome measure was final LogMAR visual acuity (VA). Results Of 24 eyes, the CNV lesion was subfoveal in 11 and extrafoveal in 13. Overall, the mean LogMAR VA at 24 months was 0.72. Extrafoveal CNV lesions achieved significantly better final VA compared with subfoveal CNV (LogMAR 0.45 vs 1.05, P ¼ 0.012). Eyes with extrafoveal CNV lesions were subdivided into foveal-sparing PDT (where the PDT laser spot did not involve the foveal center) and foveal-involved PDT (where the PDT laser covered the fovea). At all time points, the group with fovealsparing PDT had significantly better VA compared with the foveal-involved group. The final LogMAR VA for the foveal-sparing PDT group was 0.26 compared with 1.00 for the foveal-involved PDT group (P ¼ 0.003). At 24 months, 77.8% of foveal-sparing PDT cases achieved VA of Z20/40, compared with 25% of foveal-involved PDT cases and 9.1% of subfoveal CNV lesions (P ¼ 0.006). Conclusion For patients with myopic CNV, foveal-sparing PDT results in significantly better long-term visual outcomes compared with those with foveal-involved PDT. Fovealsparing PDT may be of value for treatment of myopic CNV patients who are not suitable for treatment with anti-vascular endothelial growth factor injections.

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Discussionmentioning

confidence: 99%

Comparison of foveal-sparing with foveal-involving photodynamic therapy for myopic choroidal neovascularization

Tan

Chew

2013

Eye

View full text Add to dashboard Cite

show abstract

“…Giansanti et al [10] achieved similar results, demonstrating the development of CRA in 85% of eyes and a negative influence on the change in visual acuity during 5 years of follow-up.…”

Section: Discussionsupporting

confidence: 59%

“…Very recently, some papers reported beneficial effects of PDT for myopic CNV in studies with long-term follow-up and suggested PDT as a useful option for treatment of myopic CNV, whereas other investigations reported unsatisfactory effects in the final visual outcome, confirming the results of the VIP trial [5,6,7,8,9,10]. …”

Section: Introductionsupporting

confidence: 68%

See 1 more Smart Citation

Photodynamic Therapy in Subfoveal and Juxtafoveal Myopic Choroidal Neovascularization: A 10-year Retrospective Analysis

Varano¹,

Iacono²,

Giorno³

et al. 2014

Ophthalmologica

View full text Add to dashboard Cite

The aim of this study was to evaluate and compare the effects of photodynamic therapy (PDT) in eyes with subfoveal and juxtafoveal choroidal neovascularization (CNV) secondary to pathological myopia. The study was a single-center, 10-year analysis on 19 eyes. Patients underwent best-corrected visual acuity (BCVA) measurement, slit-lamp examination, ophthalmoscopy and fluorescein angiography. Eyes with subfoveal CNV (7 eyes, 37%) progressively worsened during the 10-year follow-up from 0.68 ± 0.26 to 0.80 ± 0.47 logMAR, while in the eyes with juxtafoveal CNV (12 eyes, 63%) BCVA improved from 0.59 ± 0.42 to 0.33 ± 0.27 logMAR. Prevalence and extension of chorioretinal atrophy (CRA) were greater in eyes with subfoveal compared with juxtafoveal CNV (84 vs. 66%, respectively) and enlargement (10.05 ± 6.7 vs. 3.53 ± 4.7 mm², respectively). Our results confirm the limited long-term effectiveness of PDT in myopic subfoveal CNV. Satisfactory results can be achieved in juxtafoveal CNV with a better visual outcome and a minor CRA extension.

show abstract

Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathologic myopia

Zhu

Zhang

et al. 2014

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Long-Term Results of Photodynamic Therapy for Subfoveal Choroidal Neovascularization With Pathologic Myopia

Abstract: The results showed that visual acuity decreased significantly after a long follow-up period mainly because of the development of chorioretinal atrophy.

Cited by 31 publications

References 20 publications

Comparison of foveal-sparing with foveal-involving photodynamic therapy for myopic choroidal neovascularization

Comparison of foveal-sparing with foveal-involving photodynamic therapy for myopic choroidal neovascularization

Photodynamic Therapy in Subfoveal and Juxtafoveal Myopic Choroidal Neovascularization: A 10-year Retrospective Analysis

Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathologic myopia

Contact Info

Product

Resources

About